A Phase 1 interventional study of ITF2357 in Hepatic Impairment, sponsored by Italfarmaco. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Italfarmaco · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 in participants with chronic hepatic impairment relative to matched participants with normal hepatic function.
This study evaluated the effect of mild and moderate hepatic impairment (HI) on the pharmacokinetics of ITF2357 and its metabolites, along with the safety and tolerability in this patient population.
The total number of participants enrolled in the study was 24 subjects:
Each participant went through:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria for Participants with HI:
Female participants of non-, defined as one of the following:
Female participant of childbearing potential and male participant (if sexually active with a woman of childbearing potential and not sterile) and his partner had to agree to use an adequate and highly effective method of (according to Clinical Trials Coordination Group [CTCG] recommendations) during the study and for at least 90 days after the study drug administration for women and for men. Such methods include:
Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception.
Exclusion Criteria for Participants with HI:
Consumption of PgP or BCRP potent inducers or inhibitors that could impact the PK of the product within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic (PD) half-life of the medication before inclusion.
Note: If any of those drugs was planned to be administered in any of the potential participants, it was postponed for at least until the EOS visit is completed.
Medications that prolong the QTc interval (refer to the list provided in Section 12 of Appendix 16.1.1) within 14 days before inclusion or within 7 times the elimination half-life before inclusion.
Note: If any of those drugs was planned to be administered in any of the potential participants, it was postponed for at least until the last ECG at EOS is completed.
Inclusion Criteria for Participants with normal hepatic function:
Female participants of non-childbearing potential, defined as one of the following:
Female participant of childbearing potential and male participant (if sexually active with a woman of childbearing potential and not sterile) and his partner had to agree to use an adequate and highly effective method of contraception (according to CTCG recommendations) during the study and for at least 90 days after the study drug administration for women and for men. Such methods include:
Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM were not acceptable methods of contraception.
Exclusion Criteria for Participants with HI:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with mild HI (Child-Pugh class A)
Drug: ITF2357
Patients with moderate HI (Child-Pugh class B)
Drug: ITF2357
Participants with normal hepatic function (control group)
Drug: ITF2357
ITF2357 (INNM Givinostat hydrochloride monohydrate), single dose
Also known as: Givinostat, Givinostat hydrochloride monohydrate
Cmax of ITF2357
Maximum plasma concentration observed
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUClast of ITF2357
Area under the plasma concentration versus time curve to the real time tlast
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUC0-inf of ITF2357
Area under the plasma concentration versus time curve extrapolated to infinity
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Tmax of ITF2357
Time to reach Cmax
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
t1/2 of ITF2357
Apparent terminal half-life
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
CL/F of ITF2357
Apparent total plasma clearance from plasma
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Vz/F of ITF2357
Apparent volume of distribution
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Cmax of ITF2357 Metabolites
Maximum plasma concentration observed
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUClast of ITF2357 Metabolites
Area under the plasma concentration versus time curve to the real time tlast
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUC0-inf of ITF2357 Metabolites
Area under the plasma concentration versus time curve extrapolated to infinity
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Tmax of ITF2357 Metabolites
Time to reach Cmax
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
t1/2 of ITF2357 Metabolites
Apparent terminal half-life
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Fu of ITF2357 and Its Metabolites
Unbound fraction (fu) is the fraction of total plasma drug concentration that is not bound to plasma proteins and is pharmacologically available
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUC0-last,u of ITF2357 and Its Metabolites
Unbound area under the plasma concentration versus time curve to the real time Tlast
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
AUC0-inf,u of ITF2357 and Its Metabolites
Unbound area under the plasma concentration versus time extrapolated to infinity
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Cmax,u of ITF2357 and Its Metabolites
Unbound maximum plasma concentration observed
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
CL/Fu of ITF2357
Unbound apparent total plasma clearance
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Vz/Fu of ITF2357
Unbound apparent volume of distribution
Time frame: Pre-dose (30 minutes before administration), then 0.5 to 96-hour post-dose
Incidence of Treatment Emergent Adverse Events (TEAEs)
Number of participants with at least one related TEAEs. Treatment Emergent Adverse Event is defined as any untoward medical occurrence (including an abnormal laboratory finding, symptom or a disease) in a participant administered the pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment.
Time frame: From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Treatment-Related TEAEs
Number of participants with at least one related TEAEs
Time frame: From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Severity of Treatment Emergent Adverse Events (TEAEs)
Number of participants with at least one TEAEs according to NCI-CTCAE grade version 5.0, where severity is classified as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically significant), Grade 4 (life-threatening), and Grade 5 (death related to the adverse event).
Time frame: From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of TEAEs Leading to Withdrawal From the Study
Number of participants with at least one TEAE leading to withdrawal from the study
Time frame: From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Serious TEAEs (SAEs)
Number of participants with at least one Serious TEAE
Time frame: From screening (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality
Number of participants with at least one clinically significant laboratory parameters abnormality. The following parameters were measured: Hematology: Hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, and differential counts (basophils, eosinophils, lymphocytes, monocytes, neutrophils). Blood chemistry: Sodium, potassium, chloride, calcium, urea, creatinine, albumin, glucose, total proteins, triglycerides, total cholesterol, ALT, AST, GGT, CPK, alkaline phosphatase, total bilirubin. Coagulation: PT, INR, aPTT. Serology: HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, pregnancy test (hCG). Urinalysis: pH, protein, glucose, leukocytes, nitrites, ketones, blood. Other: Alcohol breath test; urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
Time frame: From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Clinically Significant Vital Signs Abnormality
Number of participants with at least one clinically significant vitals abnormality. The following clinical signs were measured: body temperature (C°), supine systolic blood pressure (mmHg), diastolic blood pressure (mmHg), pulse rate (beats/min), and respiratory rate (breath/min).
Time frame: From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Clinically Significant Electrocardiogram Abnormality
Number of participants with at least one clinically significant electrocardiogram abnormality. The following standard 12-lead ECG were recorded: heart rate (beats/min), PR interval (msec), QRS duration (msec), QRS axis (deg), QT interval (msec) and Fridericia and Bazett QTc interval (msec)
Time frame: From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
Incidence of Clinically Significant Physical Examination Abnormality
Number of participants with at least one clinically significant physical abnormality. A complete physical examination, including at a minimum assessments of the cardiovascular, respiratory, gastrointestinal, dermatological, neurological, and musculoskeletal systems, in addition to examinations of the head, eyes, ears, nose, throat, neck, and lymph nodes, as well as height and weight measurement.
Time frame: From Baseline (28 to 2 days before administration) to End of Study (9 to 11 days after administration)
A total of 24 participants, 8 participants in each group, were enrolled and completed the study.
| Milestone | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 |
Maximum plasma concentration observed
| ng/mL | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Cmax of ITF2357 | 42.54 ± 33.5 | 39.19 ± 54.7 | 47.21 ± 34.6 |
Area under the plasma concentration versus time curve to the real time tlast
| h*ng/mL | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| AUClast of ITF2357 | 272.17 ± 38.1 | 207.85 ± 43.3 | 306.20 ± 25.0 |
Area under the plasma concentration versus time curve extrapolated to infinity
| h*ng/mL | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| AUC0-inf of ITF2357 | 287.92 ± 36.7 | 223.54 ± 41.9 | 319.45 ± 23.7 |
Time to reach Cmax
| hours | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Tmax of ITF2357 | 2.000 ± 1.00-4.00 | 2.000 ± 0.50-4.00 | 1.000 ± 1.000-5.00 |
Apparent terminal half-life
| hours | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| t1/2 of ITF2357 | 7.8876 ± 14.5 | 7.7619 ± 22.4 | 7.0450 ± 10.6 |
Apparent total plasma clearance from plasma
| L/h | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| CL/F of ITF2357 | 173.6618 ± 36.7 | 223.6763 ± 41.9 | 156.5170 ± 23.7 |
Apparent volume of distribution
| L | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Vz/F of ITF2357 | 1976.1675 ± 31.8 | 2504.7280 ± 39.3 | 1590.7968 ± 24.0 |
Maximum plasma concentration observed
| ng/mL | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| ITF2374 | 6.34 ± 41.4 | 6.11 ± 36.5 | 7.57 ± 36.9 |
| ITF2375 | 108.28 ± 55.3 | 82.31 ± 45.6 | 125.30 ± 28.4 |
Area under the plasma concentration versus time curve to the real time tlast
| h*ng/mL | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| ITF2374 | 138.59 ± 55.3 | 118.87 ± 37.4 | 179.47 ± 75.6 |
| ITF2375 | 1160.24 ± 74.6 | 835.66 ± 47.0 | 1588.77 ± 91.3 |
Area under the plasma concentration versus time curve extrapolated to infinity
| h*ng/mL | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| ITF2374 | NA ± NA | 165.95 ± 27.2 | 239.11 ± 59.8 |
| ITF2375 | 1195.40 ± 74.5 | 865.47 ± 46.0 | 1630.94 ± 89.2 |
Time to reach Cmax
| hours | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| ITF2374 | 6.000 (4.00 to 10.00) | 5.000 (4.00 to 10.02) | 12.000 (3.00 to 24.00) |
| ITF2375 | 2.500 (2.50 to 4.00) | 3.000 (2.00 to 3.00) | 2.500 (2.03 to 10.00) |
Apparent terminal half-life
| hours | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| ITF2374 | NA ± NA | 12.3264 ± 12.0 | 14.1083 ± 47.4 |
| ITF2375 | 13.6579 ± 35.8 | 12.5157 ± 24.3 | 13.9453 ± 25.6 |
Unbound fraction (fu) is the fraction of total plasma drug concentration that is not bound to plasma proteins and is pharmacologically available
| % of unbound fraction | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| ITF2357 | 4.5044 ± 22.7 | 4.8945 ± 21.8 | 3.7642 ± 17.1 |
| ITF2374 | 8.0631 ± 14.0 | 8.5972 ± 13.6 | 7.4527 ± 18.7 |
| ITF2375 | 1.1150 ± 11.9 | 1.2801 ± 19.2 | 1.0433 ± 11.6 |
Unbound area under the plasma concentration versus time curve to the real time Tlast
| h*ng/mL | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| ITF2357 | 12.26 ± 41.5 | 10.17 ± 35.5 | 11.53 ± 36.2 |
| ITF2374 | 11.18 ± 54.2 | 10.47 ± 37.9 | 13.38 ± 86.1 |
| ITF2375 | 12.94 ± 65.5 | 10.70 ± 46.3 | 16.58 ± 86.5 |
Unbound area under the plasma concentration versus time extrapolated to infinity
| h*ng/mL | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| ITF2357 | 12.97 ± 40.1 | 10.94 ± 34.7 | 12.02 ± 34.8 |
| ITF2374 | NA ± NA | 12.72 ± 31.8 | 17.73 ± 58.8 |
| ITF2375 | 13.33 ± 65.4 | 11.08 ± 45.4 | 17.02 ± 84.6 |
Unbound maximum plasma concentration observed
| ng/mL | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| ITF2357 | 1.92 ± 44.4 | 1.92 ± 46.5 | 1.78 ± 37.6 |
| ITF2374 | 0.51 ± 46.6 | 0.52 ± 30.8 | 0.56 ± 41.6 |
| ITF2375 | 1.21 ± 53.2 | 1.05 ± 45.9 | 1.31 ± 27.9 |
Unbound apparent total plasma clearance
| L/h | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| CL/Fu of ITF2357 | 3855.3955 ± 40.1 | 4569.9699 ± 34.7 | 4158.0773 ± 34.8 |
Unbound apparent volume of distribution
| L | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Vz/Fu of ITF2357 | 43872.1021 ± 37.8 | 51174.5320 ± 34.1 | 42261.5883 ± 35.8 |
Number of participants with at least one related TEAEs. Treatment Emergent Adverse Event is defined as any untoward medical occurrence (including an abnormal laboratory finding, symptom or a disease) in a participant administered the pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment.
| Participants | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Incidence of Treatment Emergent Adverse Events (TEAEs) | 0 | 2 | 1 |
Number of participants with at least one related TEAEs
| Participants | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Incidence of Treatment-Related TEAEs | 0 | 0 | 0 |
Number of participants with at least one TEAEs according to NCI-CTCAE grade version 5.0, where severity is classified as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically significant), Grade 4 (life-threatening), and Grade 5 (death related to the adverse event).
| Participants | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Grade 1 | 0 | 2 | 0 |
| Grade 2 | 0 | 0 | 1 |
| Grade ≥ 3 | 0 | 0 | 0 |
Number of participants with at least one TEAE leading to withdrawal from the study
| Participants | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Incidence of TEAEs Leading to Withdrawal From the Study | 0 | 0 | 0 |
Number of participants with at least one Serious TEAE
| Participants | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Incidence of Serious TEAEs (SAEs) | 0 | 0 | 0 |
Number of participants with at least one clinically significant laboratory parameters abnormality. The following parameters were measured: Hematology: Hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, and differential counts (basophils, eosinophils, lymphocytes, monocytes, neutrophils). Blood chemistry: Sodium, potassium, chloride, calcium, urea, creatinine, albumin, glucose, total proteins, triglycerides, total cholesterol, ALT, AST, GGT, CPK, alkaline phosphatase, total bilirubin. Coagulation: PT, INR, aPTT. Serology: HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, pregnancy test (hCG). Urinalysis: pH, protein, glucose, leukocytes, nitrites, ketones, blood. Other: Alcohol breath test; urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
| Participants | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality | 0 | 0 | 0 |
Number of participants with at least one clinically significant vitals abnormality. The following clinical signs were measured: body temperature (C°), supine systolic blood pressure (mmHg), diastolic blood pressure (mmHg), pulse rate (beats/min), and respiratory rate (breath/min).
| Participants | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Incidence of Clinically Significant Vital Signs Abnormality | 0 | 0 | 0 |
Number of participants with at least one clinically significant electrocardiogram abnormality. The following standard 12-lead ECG were recorded: heart rate (beats/min), PR interval (msec), QRS duration (msec), QRS axis (deg), QT interval (msec) and Fridericia and Bazett QTc interval (msec)
| Participants | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Incidence of Clinically Significant Electrocardiogram Abnormality | 0 | 0 | 0 |
Number of participants with at least one clinically significant physical abnormality. A complete physical examination, including at a minimum assessments of the cardiovascular, respiratory, gastrointestinal, dermatological, neurological, and musculoskeletal systems, in addition to examinations of the head, eyes, ears, nose, throat, neck, and lymph nodes, as well as height and weight measurement.
| Participants | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| Incidence of Clinically Significant Physical Examination Abnormality | 0 | 0 | 0 |
Collected over AEs were recorded from the time of informed consent through the EOS visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mild HI | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Moderate HI | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Healthy Volunteers | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Event | Mild HI | Moderate HI | Healthy Volunteers |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/8 | 1/8 | 0/8 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/8 | 1/8 | 0/8 |
| Oral candidiasisInfections and infestations | 0/8 | 0/8 | 1/8 |
| Age, Continuous(year) | Mild HI | Moderate HI | Healthy Volunteers | Total |
|---|---|---|---|---|
| Mean | 54.1 ± 8.44 | 61.9 ± 7.51 | 38.6 ± 13.09 | 51.5 ± 13.73 |
| Sex: Female, Male(Participants) | Mild HI | Moderate HI | Healthy Volunteers | Total |
|---|---|---|---|---|
| Female | 3 | 3 | 4 | 10 |
| Male | 5 | 5 | 4 | 14 |
| Race (NIH/OMB)(Participants) | Mild HI | Moderate HI | Healthy Volunteers | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 3 | 3 |
| White | 8 | 8 | 5 | 21 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Mild HI | Moderate HI | Healthy Volunteers | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 8 | 8 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Weight(kg) | Mild HI | Moderate HI | Healthy Volunteers | Total |
|---|---|---|---|---|
| Weight at screening | 77.89 ± 22.701 | 78.98 ± 21.303 | 79.04 ± 2.274 | 78.63 ± 17.228 |
| Weight at D-1 | 77.71 ± 22.502 | 79.04 ± 21.140 | 79.54 ± 1.907 | 78.76 ± 17.074 |
| BMI(kg/m2) | Mild HI | Moderate HI | Healthy Volunteers | Total |
|---|---|---|---|---|
| BMI at screening | 26.605 ± 6.2639 | 27.248 ± 6.2722 | 26.653 ± 2.1064 | 26.835 ± 5.0353 |
| BMI at D-1 | 26.553 ± 6.2306 | 27.273 ± 6.2001 | 26.823 ± 2.1284 | 26.883 ± 4.9985 |
| Child-Pugh score(Scores on a scale (5 to 15)) | Mild HI | Moderate HI | Healthy Volunteers | Total |
|---|---|---|---|---|
| Child-Pugh score at screening | 5.00 ± 0.000 | 7.13 ± 0.354 | — | 6.06 ± 1.124 |
| Child-Pugh score at D-1 | 5.00 ± 0.000 | 7.38 ± 0.518 | — | 6.19 ± 1.276 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2025 to primary completion in Aug 2025, 2 months.
Results were first posted in Jun 2026, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat